Parkinson's Disease
Conditions
Brief summary
The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).
Detailed description
Periodical measures of the clinical features with UPDRS will be done at the beginning, each three months until two years. Each group will be compare to evaluate.
Interventions
DIETARY_SUPPLEMENTVIUSID/ALZER
VIUSID/ALZER, 3 per day, oral, one year
DIETARY_SUPPLEMENTPlacebo
Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
Sponsors
Catalysis SL
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with clinical of PD, with the criteria of Brain Bank of London with early stage. * Informed consent.
Exclusion criteria
* Presence of another disease not well controlled. * Patient with atypical features. * Patient with advanced Parkinson's disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment) | one year |
Secondary
| Measure | Time frame |
|---|---|
| Hoehn-Yarh will be done at the beginning, every three months until one year (end of the treatment) | one year |
| Dosage levodopa will be done at the beginning, every three months until one year (end of the treatment) | one year |
Countries
Cuba
Outcome results
None listed